Goldman Sachs cuts Fleury SA stock rating to neutral, lowers PT

Published 30/05/2025, 08:14
Goldman Sachs cuts Fleury SA stock rating to neutral, lowers PT

On Friday, Goldman Sachs revised its stance on Fleury SA (FLRY3:BZ), downgrading the stock from Buy to Neutral and adjusting the price target to R$15.00 from the previous R$16.00. The research firm points to a solid market position for Fleury in the healthcare sector, acknowledging the company’s superior brand perception compared to its competitors. Despite this, analysts predict that growth and profitability for the year 2025 will be subdued, particularly due to the underwhelming performance of the premium brand, which historically has been more profitable.

The premium segment of Fleury’s business is facing stagnation within Brazil’s healthcare market, where the company already holds a significant share. Goldman Sachs provided an analysis showing that the expected growth and margin dynamics for each of Fleury’s business divisions indicate a flat consolidated EBITDA margin in the near term.

Moreover, the firm anticipates that the premium brand will confront two specific challenges in the second quarter of 2025. Firstly, the brand is up against a tougher growth comparison base from the same quarter in the previous year. The premium brand experienced a 5.7% year-over-year growth in the first quarter of 2025, which was measured against a 2.3% year-over-year in the first quarter of 2024. Now, it faces a comparison to a 6.1% year-over-year growth in the second quarter of 2024. Secondly, a calendar effect is expected to impact the brand negatively, as the second quarter of 2025 is forecasted to have two fewer business days compared to the year prior, which could potentially reduce service frequency.

Goldman Sachs’ updated analysis reflects a cautious outlook for Fleury’s performance in the near future, with specific emphasis on the challenges facing the company’s premium brand within a competitive and evolving healthcare market in Brazil.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.